Lord, Abbett & Co
JUNO

Lord, Abbett & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

Lord, Abbett & Co’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-479,640
Closed -$21.9M – 950
2017
Q4 		$21.9M Buy
+479,640
New +$23.9M 0.06% 450
2016
Q3 		– Sell
-688,876
Closed -$26.5M – 970
2016
Q2 		$26.5M Buy
688,876
+475,553
+223% +$19.7M 0.08% 356
2016
Q1 		$8.13M Sell
213,323
-178,370
-46% -$6.22M 0.03% 615
2015
Q4 		$17.2M Buy
391,693
+124,595
+47% +$6.18M 0.05% 474
2015
Q3 		$10.9M Sell
267,098
-371,227
-58% -$16.3M 0.03% 569
2015
Q2 		$34M Sell
638,325
-74,478
-10% -$3.95M 0.09% 355
2015
Q1 		$43.2M Buy
712,803
+693,014
+3,502% +$33.6M 0.11% 290
2014
Q4 		$1.03M Buy
+19,789
New +$886K ﹤0.01% 895

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Lord, Abbett & Co's JUNO Position: Q1 2018 in Review

Lord, Abbett & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 479,640 shares — an estimated $21.9M sold.

Lord, Abbett & Co first reported a position in JUNO in Q4 2014 and held it in 8 quarters. The position peaked at $43.2M in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Lord, Abbett & Co reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 479,640 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $21.9M.
  • Lord, Abbett & Co first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 8 quarters.
  • Lord, Abbett & Co's Juno Therapeutics, Inc. position peaked at $43.2M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Lord, Abbett & Co's 13F filing for Q1 2018, filed 15 May 2018.